Table IV.

PFS on the last regimen before enrolling the study and on dTCApFs.

Patient no.	PFS on the last regimen pre-enrollment, days	PFS on dTCApFs, days
1	480	53
2	134	25
3	110	170
4	0	330
5	52	51
6	384	110
7	54	90
8	80	52
9	375	60
10	1,800	14
11	41	52
12	42	50
13	96	42
14	365	40
15	1	80
16	105	45
17	564	41

Rows with bold print represent patients who experienced PFS on dTCApFs, which was comparable with or exceeded that of their last regimen pre-enrollment. PFS, progression-free survival.